LOXL1-AS1 Contributes to Non-Small Cell Lung Cancer Progression by Regulating miR-3128/RHOXF2 Axis. 2020

Limin Zhao, and Xuefei Zhang, and Huannan Guo, and Mingyang Liu, and Liming Wang
Department of Oncology, General Hospital of Heilongjiang General Administration of Agriculture and Reclamation, Harbin 150088, People's Republic of China.

OBJECTIVE The purpose of this study was to investigate the molecular mechanism of LncRNA LOXL1-AS1 in non-small cell lung cancer (NSCLC). METHODS Lung cancer cell lines (H1299, A549, H520 and H596) and human normal lung epithelial cell line (BEAS-2B) were used in this study. Gene expression was measured by qRT-PCR (quantitative real-time PCR). The bioinformatics databases (miRDB and TargetScan7) were used to predict target genes. Luciferase assay and pull-down assay were processed for verifying the binding sites. CCK8 assay was used for detecting proliferation, and transwell assay was undertaken for migration and invasion. RESULTS LncRNA LOXL1-AS1 was higher expressed in lung cancer tissues and cells. Moreover, LOXL1-AS1 expression was upregulated in tumor tissues with advanced stages and metastasis. After knocking down LOXL1-AS1, proliferation, invasion and migration of H1299 and A549 cells were inhibited. Interestingly, miR-3128 was negatively regulated by LncRNA LOXL1-AS1, which inhibited the expression of RHOXF2. Rescue assay also confirmed that miR-3128 inhibitor and oeRHOXF2 could rescue the effect of down-regulated LOXL1-AS1 on proliferation, invasion and migration progression. CONCLUSIONS LOXL1-AS1 promotes the progression of NSCLC by regulating miR-3128/RHOXF2 axis, which might be a new potential target for the diagnosis and treatment of NSCLC.

UI MeSH Term Description Entries

Related Publications

Limin Zhao, and Xuefei Zhang, and Huannan Guo, and Mingyang Liu, and Liming Wang
July 2020, Neoplasma,
Limin Zhao, and Xuefei Zhang, and Huannan Guo, and Mingyang Liu, and Liming Wang
November 2020, Pathology, research and practice,
Limin Zhao, and Xuefei Zhang, and Huannan Guo, and Mingyang Liu, and Liming Wang
March 2020, Thoracic cancer,
Limin Zhao, and Xuefei Zhang, and Huannan Guo, and Mingyang Liu, and Liming Wang
December 2022, Biochemical genetics,
Limin Zhao, and Xuefei Zhang, and Huannan Guo, and Mingyang Liu, and Liming Wang
January 2020, OncoTargets and therapy,
Limin Zhao, and Xuefei Zhang, and Huannan Guo, and Mingyang Liu, and Liming Wang
December 2021, Oncology letters,
Limin Zhao, and Xuefei Zhang, and Huannan Guo, and Mingyang Liu, and Liming Wang
January 2019, OncoTargets and therapy,
Limin Zhao, and Xuefei Zhang, and Huannan Guo, and Mingyang Liu, and Liming Wang
January 2020, Cancer biomarkers : section A of Disease markers,
Limin Zhao, and Xuefei Zhang, and Huannan Guo, and Mingyang Liu, and Liming Wang
January 2023, OncoTargets and therapy,
Copied contents to your clipboard!